机构：[a]Department of Orthopaedics, Beijing Tian Tan Hospital, Capital Medical University, Beijing 100050, China诊疗科室骨科首都医科大学附属天坛医院[b]Department of Orthopaedics, Air Force General Hospital, People's Liberation Army of China, Beijing 100142, China
Osteosarcoma (OS) is the most common type of malignant bone tumor in children and adolescents. However, the molecular mechanism underlying OS development is unclear. Here, we investigated the contribution of lncRNA-p21, a novel long non-coding RNA, on OS cell proliferation. Our results demonstrated that the expression of lncRNA-p21 was repressed in OS tissue. Growth curves and the cell colony formation assay showed that lncRNA-p21 significantly inhibited the proliferation of OS cell lines. In addition, the expression of lncRNA-p21 increased the protein levels of proliferation markers, such as Ki-67 and cyclin D1. Subsequently, lncRNA-p21 overexpression up-regulated the protein level of phosphatase and tensin homolog deleted on chromosome ten (PTEN), a well-known inhibitor of AKT signaling. Moreover, our gain and loss function assay showed that the promotion of PTEN by lncRNA-p21 was mediated by miR-130b, an oncogene overexpressed in OS tissue. Our findings may provide a novel lncRNA-targeted therapy for patients with OS.
基金：
National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China [81401831]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|3 区医学
小类|3 区药学4 区医学：研究与实验
最新[2023]版：
大类|2 区医学
小类|1 区药学2 区医学：研究与实验
JCR分区：
出版当年[2016]版：
Q2MEDICINE, RESEARCH & EXPERIMENTALQ2PHARMACOLOGY & PHARMACY
最新[2023]版：
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者机构：[a]Department of Orthopaedics, Beijing Tian Tan Hospital, Capital Medical University, Beijing 100050, China
通讯作者：
通讯机构：[b]Department of Orthopaedics, Air Force General Hospital, People's Liberation Army of China, Beijing 100142, China
推荐引用方式(GB/T 7714)：
Han Weifeng,Liu Junpeng.LncRNA-p21 inhibited the proliferation of osteosarcoma cells via the miR-130b/PTEN/AKT signaling pathway[J].BIOMEDICINE & PHARMACOTHERAPY.2018,97:911-918.doi:10.1016/j.biopha.2017.11.014.
APA：
Han, Weifeng&Liu, Junpeng.(2018).LncRNA-p21 inhibited the proliferation of osteosarcoma cells via the miR-130b/PTEN/AKT signaling pathway.BIOMEDICINE & PHARMACOTHERAPY,97,
MLA：
Han, Weifeng,et al."LncRNA-p21 inhibited the proliferation of osteosarcoma cells via the miR-130b/PTEN/AKT signaling pathway".BIOMEDICINE & PHARMACOTHERAPY 97.(2018):911-918
医学